was significant intra-individual variation of FC within CD patients, this could impact on the interpretation of single values in isolation. A prospective study to evaluate the degree of variability of FC in three consecutive days stool samples in CD patients in clinical remission was performed.

Methods 143 patients with CD in remission (CDAI <150, no escalation of medical therapy within 3 months) who were attending for routine follow-up were identified and enrolled. Patients were excluded if they were taking NSAIDs or developed any change in symptoms over the 3-day collection period. After informed consent, patients were asked to provide stool samples from three consecutive days for analysis. FC was analysed using the Buhlman FC ELISA as per the manufacturer's instructions.

Results Of the 143 patients recruited 34 did not return any samples, 6 returned less than the required number of stool samples, 2 withdrew consent and 2 developed clinical evidence of a flare of disease during the collection period and were excluded from analysis. Therefore 98 complete sets of three stool samples were obtained and analysed. The intraclass correlation coefficient of the 3 FC values, log-transformed, was 0.842 with corresponding 95% CI 0.788 to 0.886 showing that consistency between the three log-transformed FC measurements is high. The reliability of a "normal" FC result of <50 and of <100 was assessed using the κ statistic for agreement between the three measurements. For a FC result of <50 κ was 0.648 (95% CI 0.508 to 0.770) and for a FC result of <100, κ was 0.603 (95% CI 0.483 to 0.712) demonstrating that there is moderately good and similar levels of agreement across the 3 samples for both measures. The reliability of the cut-off of 50 is slightly better than the cut-off of 100.

Conclusion The consistency of three faecal calprotectin samples over three consecutive days is high and the CI is narrow suggesting that in a larger population consistency would also be high. This indicates that there is little intra-individual variability of the test and a one off sample can indeed provide reliable information for use in clinical practice. Higher inpatient variability of high FC values suggests that the log-transformed values are more reliable.

Competing interests None declared.

PTU-107 WEIGHT ADJUSTED ANTI-TNF THERAPY FAVOURS OBESE PATIENTS WITH CROHN'S DISEASE

doi:10.1136/gutjnl-2012-302514c.107

¹M Bhalme,* ²A Sharma, ³R Keld, ⁴A Makin, ⁴R Willert, ⁴S Campbell. ¹North Manchester General Hospital, Manchester, Manchester, UK; ²Royal Preston Hospital, Preston, UK; ³Royal Albert Edward Infirmary, Wigan, UK; ⁴Manchester Royal Infirmary, Manchester, UK

Introduction Adalimumab (Humira, Abbott) is a novel subcutaneous anti-TNF agent, effective in inducing and maintaining remission in Crohn's disease (CD). Unlike Infliximab (IFx), Adalimumab (Ad) dosing is not weight adjusted, and dose frequency is based on clinical response. Pharmacokinetic analyses in rheumatoid arthritis patients (pts) has shown weight to have minimal effect on Ad clearance. Our aim was to determine whether weight is important in predicting efficacy of weight adjusted and non-weight adjusted anti-TNF treatment in CD.

Methods A hospital database of CD patients receiving anti-TNF therapy was analysed retrospectively. Demographics, previous IFx exposure, disease anatomy, concomitant immunosuppressive therapy, smoking status and duration of anti-TNF treatment were recorded. A body mass index (BMI) cut off of <30 or ≥30 was used to define obesity and time to dose escalation (increased frequency) and survival curve analysis were compared using Kaplan-Meier (KM) estimation. $p < 0.05$ was taken as significant. Analysis were made using Graphpad prism software.

Results Adalimumab patients: 54 (36 female; age range 17–72 years, median 38.5; BMI range 17.2–47.7, median 24.8) patients details were available. 46 patients had BMI <30 and 8 had BMI ≥30. CD distribution and activity were heterogeneous. There was no significant difference ($p = \text{NS}$) in the duration of Ad treatment in BMI <30 (range 1–39 months, median 10.5) vs BMI ≥30 (range 6–27 months, median 13.5). KM estimation revealed a significantly lower time to Ad dose escalation in the BMI ≥30 (χ^2 6.117, $p = 0.0134$). There was no difference in time to dose escalation according to disease anatomy or smoking status. Infliximab patients: 76 (42 female; age range 11–70 years, median 37.5; BMI range 14.9–43.7, median 23.7) patients details were available. 62 patients had BMI <30 and 14 had BMI ≥30. CD distribution and activity were heterogeneous. KM estimation revealed the survival curves for the IFx patients were close and statistically non-significant (χ^2 1.933, $p = \text{NS}$), in BMI <30 and BMI ≥30.

Conclusion Patients BMI appears important in predicting Adalimumab efficacy in CD with respect to loss of response (LOR), irrespective of induction dosing. Weight adjusted anti-TNF treatment appears to overcome this apparent reduction of efficacy in obese patients, as demonstrated by the data. A trend for separation between the two groups may be explained by the additional effects of the pro-inflammatory adipokines in obese patients with CD. A prospective study on the effect of weight on drug response is warranted.

Competing interests None declared.

PTU-108 INDUCTION OF REMISSION WITH ADALIMUMAB IN PATIENTS WITH MODERATE CROHN'S DISEASE: SUBANALYSIS OF CLASSIC I

doi:10.1136/gutjnl-2012-302514c.108

¹W J Sandborn, ²J-F Colombel, ³M M Castillo,* ³Q Zhou, ³R B Thakkar. ¹Gastroenterology, University of California San Diego, San Diego, California, USA; ²Hepato-gastroenterology, Centre Hospitalier Universitaire de Lille, Lille, France; ³Abbott, Abbott Park, USA

Introduction CLASSIC I,¹ a randomised, double-blind, placebo-controlled, dose-ranging trial, demonstrated that adalimumab (ADA) 160 mg at week 0, followed by 80 mg at week 2 is the optimal induction regimen in anti-TNF-naïve patients with moderate to severe Crohn's disease (CD). It also showed that patients with baseline C reactive protein (CRP) concentration ≥10 mg/l achieved higher rates of clinical remission (CDAI score <150) at week 4.

Methods This post hoc analysis evaluated efficacy in patients with moderate CD (baseline CDAI ≤300) and whether elevated CRP (≥10 mg/l) in this subgroup would similarly improve efficacy, compared with results for patients with severe CD. Clinical remission at week 4 was assessed for patients who received induction with ADA (160 mg/80 mg or 80 mg/40 mg) or placebo in CLASSIC I. Patients with the following characteristics were included in the analysis: baseline CRP ≥10 mg/l; moderate CD (baseline CDAI ≤300); moderate CD with baseline CRP ≥10 mg/l; severe CD (baseline CDAI >300); and severe CD with baseline CRP ≥10 mg/l.

Results In CLASSIC I, ADA 160 mg/80 mg was effective at inducing remission in all subgroups studied, including the subgroup of patients with moderate CD; in this subgroup, high baseline CRP was associated with substantially higher remission rates. This analysis suggests that patients with moderate disease can be treated effectively with adalimumab, especially when there is evidence of inflammation. Prospective studies are warranted to confirm these findings.

Conclusion In CLASSIC I, ADA 160 mg/80 mg was effective at inducing remission in all subgroups studied, including the subgroup

of patients with moderate CD; in this subgroup, high baseline CRP was associated with substantially higher remission rates. This analysis suggests that patients with moderate disease can be treated effectively with adalimumab, especially when there is evidence of inflammation. Prospective studies are warranted to confirm these findings.

Abstract PTU-108 Table 1 Per cent of patients in clinical remission at week 4

	Placebo	ADA80/40	ADA160/80
All patients	12% (9/74)	24% (18/75)	36% (27/76)†
CRP ≥ 10 mg/l, % (n/N)	4% (1/28)	27% (9/33)*	43% (12/28)†
CDAI ≤ 300 , % (n/N)	17% (8/46)	29% (13/45)	46% (19/41)†
CRP ≥ 10 mg/l, CDAI ≤ 300 , % (n/N)	7% (1/15)	26% (6/23)	57% (8/14)†
CDAI > 300 , % (n/N)	4% (1/28)	17% (5/30)	23% (8/35)*
CRP ≥ 10 mg/l, CDAI > 300 , % (n/N)	0% (0/13)	30% (3/10)	29% (4/14)

*p<0.05 vs placebo.

†p<0.005 vs placebo.

Competing interests W Sandborn: Grant/Research Support from: Centocor Ortho Biotech, Abbott Laboratories, and UCB Pharma., Consultant for: Centocor Ortho Biotech, Abbott Laboratories, UCB Pharma, and Merck (previously Schering Plough), J-F Colombel: Shareholder with: Intestinal Biotech Development, Grant/Research Support from: Astra-Zeneca, Danisco, Danone, Dysphar, Ferring, Giuliani, Lesaffre, Mapi Naxis, Ocerra Therapeutics, Roquette, Schering-Plough and UCB, Consultant for: Abbott Laboratories, ActoGenix NV, Albireo Pharma, Astra Zeneca, Bayer Schering Pharma, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Centocor, Chemocentryx, Cosmo Technologies, Danone France, Elan, Genentech, Giuliani, Given Imaging, GlaxoSmithKline, Merck, Millennium, NeoVacs, Ocerra, Otsuka American, PDL Biopharma, Pfizer, Ribo Vacs Biotech, Schering-Plough, Shire, Synta, Teva and Petah Tikva, Therakos, UCB, and Wyeth, Speaker bureau with: Abbott Laboratories, Astra Zeneca, Centocor, Elan, Falk, Ferring, Given Imaging, Otsuka American, PDL, Schering-Plough, Shire and UCB, M Castillo Shareholder with: Abbott, Employee of: Abbott, Q Zhou Employee of: Abbott, R Thakkar Shareholder with: Abbott, Employee of: Abbott.

REFERENCE

1. Hanauer SB. *Gastroenterology* 2006;**130**:323.

PTU-109

EFFICACY AND SAFETY OF ADALIMUMAB IN MODERATE COMPARED WITH SEVERE CROHN'S DISEASE: POOLED DATA FROM THE CHARM AND EXTEND TRIALS

doi:10.1136/gutjnl-2012-302514c.109

¹J-F Colombel, ²W J Sandborn, ³M M Castillo,* ³Q Zhou, ³R B Thakkar. ¹Hepato-gastroenterology, Centre Hospitalier Universitaire de Lille, Lille, France; ²Gastro-entology, University of California San Diego, San Diego, California, USA; ³Abbott, Abbott Park, USA

Introduction The efficacy of adalimumab (ADA) in Crohn's disease (CD) by disease duration has been explored,¹ but efficacy and safety of ADA by disease severity have not been investigated. The CHARM² and EXTEND³ trials assessed ADA treatment for the maintenance of remission in patients with moderate to severe CD. Results from CHARM and EXTEND in patients with moderate vs severe CD were pooled to assess efficacy and safety by disease severity.

Methods This analysis of pooled data were performed to assess clinical response and clinical remission at week 56 (CHARM) or 52 (EXTEND) in patients with moderate (CDAI ≤ 300) or severe (CDAI > 300) CD, treated with blinded ADA every other week (eow) or placebo. In both trials, patients received open-label ADA induction (CHARM: 80 mg at week 0, 40 mg at week 2; EXTEND: 160 mg at week 0, 80 mg at week 2), followed by blinded treatment (ADA 40 mg eow or weekly, or placebo in CHARM, 40 mg eow or

placebo in EXTEND) from weeks 4 to the end of the trial (week 56 in CHARM, week 52 in EXTEND). Data from the ADA 40 mg eow arm of CHARM was pooled with data from EXTEND; safety and efficacy (proportion of patients in clinical remission, defined as CDAI ≤ 150 , or clinical response, defined as at least a 70 point decrease in CDAI [CR70]) at week 56/52 were assessed for patients who achieved CR70 at week 4, separated by baseline disease severity (moderate or severe).

Results A total of 438 patients were included in the pooled analysis: 187 with moderate CD (placebo: 92; ADA: 95) and 251 with severe CD (placebo: 126; ADA: 125). For both moderate and severe CD groups, a statistically significantly greater proportion of patients treated with ADA 40 mg eow achieved clinical response and clinical remission at week 56/52 compared with placebo treated patients (Abstract PTU-109 table 1). The safety profiles in the moderate and severe CD subgroups were similar.

Abstract PTU-109 Table 1 Clinical response (CR70) and clinical remission at week 56/52, by baseline CDAI: pooled data from CHARM and EXTEND

	CDAI ≤ 300			CDAI > 300		
	Placebo	ADA 40 mg eow	p Value*	Placebo	ADA 40 mg eow	p Value*
CR70 (%)	16	44	<0.001	14	44	<0.001
Clinical remission (%)	14	40	<0.001	7	34	<0.001

*ADA vs placebo.

Conclusion The analysis of the pooled data from CHARM and EXTEND suggests that ADA 40 mg eow is safe and effective for the treatment of either moderate or severe CD.

Competing interests J-F Colombel Shareholder with: Intestinal Biotech Development, Grant/Research Support from: Astra-Zeneca, Danisco, Danone, Dysphar, Ferring, Giuliani, Lesaffre, Mapi Naxis, Ocerra Therapeutics, Roquette, Schering-Plough, and UCB, Consultant for: Abbott Laboratories, ActoGenix NV, Albireo Pharma, Astra Zeneca, Bayer Schering Pharma, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Centocor, Chemocentryx, Cosmo Technologies, Danone France, Elan, Genentech, Giuliani, Given Imaging, GlaxoSmithKline, Merck, Millennium, NeoVacs, Ocerra, Otsuka American, PDL Biopharma, Pfizer, Ribo Vacs Biotech, Schering-Plough, Shire, Synta, Teva and Petah Tikva, Therakos, UCB, and Wyeth, Speaker bureau with: Abbott Laboratories, Astra Zeneca, Centocor, Elan, Falk, Ferring, Given Imaging, Otsuka American, PDL, Schering-Plough, Shire and UCB, W Sandborn Grant/Research Support from: Centocor Ortho Biotech, Abbott Laboratories, and UCB Pharma, Consultant for: Centocor Ortho Biotech, Abbott Laboratories, UCB Pharma, and Merck (previously Schering Plough), M Castillo Shareholder with: Abbott, Employee of: Abbott, Q Zhou Employee of: Abbott, R Thakkar Shareholder with: Abbott, Employee of: Abbott.

REFERENCES

1. Schreiber S. *Gastroenterology* 2007;**132**:A-147.
2. Colombel JF. *Gastroenterology* 2007;**132**:52.
3. Rutgeerts P. *Gastroenterology* 2009;**136**:A-116.

PTU-110

ELEVATED C REACTIVE PROTEIN IN ANTI-TNF-NAIVE PATIENTS IS ASSOCIATED WITH HIGHER REMISSION RATES

doi:10.1136/gutjnl-2012-302514c.110

¹W J Sandborn, ²J-F Colombel, ³M M Castillo,* ³Q Zhou, ³R B Thakkar. ¹Gastro-entology, University of California San Diego, San Diego, California, USA; ²Hepato-gastroenterology, Centre Hospitalier Universitaire de Lille, Lille, France; ³Abbott, Abbott Park, USA

Introduction The CHARM trial¹ demonstrated that adalimumab (ADA) was effective for the maintenance of remission in patients with moderate to severe Crohn's disease (CD), and that remission rates are influenced by a patient's baseline C reactive protein (CRP)